A Randomized, Double-Blind, Placebo Controlled, Parallel-Group, Phase II Trial of JKB-121 for the Treatment of Nonalcoholic Steatohepatitis (NASH)
Active, no longer recruiting
Phase of Trial: Phase II
Latest Information Update: 09 Aug 2017
At a glance
- Drugs Nalmefene (Primary)
- Indications Non-alcoholic steatohepatitis
- Focus Adverse reactions
- 04 Aug 2017 Planned primary completion date changed from 31 Jul 2017 to 1 Sep 2017.
- 10 Jun 2017 Biomarkers information updated
- 26 Jan 2017 Planned End Date changed from 1 Dec 2016 to 31 Dec 2017.